moderate - Elective ophthalmic procedures exhibit some economic sensitivity as patients may defer cataract surgery (often bundled with MIGS) or dry eye treatments during recessions. However, glaucoma progression creates clinical urgency that limits deferral rates. Medicare coverage (65+ demographic represents 70%+ of glaucoma patients) provides downside protection versus purely cosmetic procedures. ASC utilization rates correlate with consumer confidence and employment-linked insurance coverage.

Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impactful given negative FCF and -8% FCF yield; (2) Increased financing costs for ASCs and ophthalmology practices may slow capital equipment purchases; (3) Competition for investor capital shifts toward profitable businesses as cost of capital rises. The company's 9.60x current ratio provides liquidity buffer, but eventual need for growth capital becomes more expensive in higher rate environment.

growth - Attracts speculative growth investors and healthcare-focused funds willing to accept deep losses for potential market share gains in underpenetrated MIGS market. The 103% one-year return despite negative fundamentals indicates momentum/technical trading activity. Not suitable for value or income investors given negative earnings, no dividend, and uncertain path to profitability. Requires 3-5 year investment horizon for commercial execution story to play out.